Amneal Pharmaceuticals, Inc. Class A Common Stock — Graphique, cours et actualités (NASDAQ:AMRX)

Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques

Trimestriel Annuel

Market Capitalization 4.21 B
Employee 8 500
Founded 2002
CEO Chintu PatelChirag Patel
Website www.amneal.com
Headquarter N/A
FIGI BBG00462PGG0
Industry Fabricants de Médicaments — Spécialités et Génériques

Chiffre d'affaires total

Résultat net

Bénéfice par action de base (BPA de base)

Dette totale

Flux de trésorerie disponible

Trésorerie et équivalents de trésorerie

ratio cours/bénéfice

57.27

ratio cours/chiffre d'affaires

1.36

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.

AMRX

Financials

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Nouvelles

Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now?

Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term

3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)

Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?

Teva’s CNS Portfolio Is Growing, But Valuation Is Stretched (NYSE:TEVA)

Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)

Do Options Traders Know Something About Amneal Stock We Don't?

Amneal Pharma dépasse les prévisions de BPA au T1 2026

Amneal T1 2026 : accord de 750 M$ avec Kashiv crée un leader des biosimilaires

Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes"

Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High?

Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy?